Developing new therapies that aim to preserve kidney function and prevent progression to kidney failure
We are focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by our passion for ground-breaking science and innovation, we strive to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Our most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.